Ototoxicity Monitoring in South African Cancer Facilities: A National Survey
Overview
Affiliations
Background: National information regarding ototoxicity monitoring practices are limited for patients undergoing chemotherapy in South Africa.
Objectives: To determine (1) the national status of ototoxicity monitoring implemented in private and public cancer facilities, (2) the knowledge and ototoxicity monitoring approaches implemented, and (3) reported challenges.
Method: A descriptive quantitative survey was conducted in public and private oncology units and audiology referral clinics. Private (60%) and public (43%) oncology units that provide platinum-based chemotherapy in South Africa and audiology referral units (54%) were: (1) surveyed telephonically to determine if ototoxicity monitoring takes place; and (2) a self-administered survey was sent to qualifying oncology units and audiology referral clinics.
Results: All public oncology units reported that ototoxicity monitoring only occurs on referral and is not standard practice. All private oncology units indicated that monitoring is on a patient self-referral basis when symptoms occur. Poor awareness of ototoxicity monitoring best practice guidelines was reported by all oncology units and 14% of audiology referral clinics. Audiology referral clinics reported adequate knowledge of ototoxicity protocols although they are not widely used with only 43% following best practice guidelines. The most prominent challenges reported by participants was referral system (67% oncology units; 57% audiology referral clinics), environmental noise (83% oncology units; 86% audiology referral clinics) and the compromised status of cancer patients (67% oncology units; 57% audiology referral clinics).
Conclusion: Ototoxicity monitoring is not routinely implemented across oncology units in South Africa. Multidisciplinary teamwork and a simplified national ototoxicity monitoring protocol may improve hearing outcomes for patients.
Healthcare professionals' knowledge and practices in managing ototoxicity in children with cancer.
Ramnarian K, Paken J S Afr J Commun Disord. 2024; 71(1):e1-e15.
PMID: 39625086 PMC: 11622129. DOI: 10.4102/sajcd.v71i1.1064.
Roadmap to a Global Template for Implementation of Ototoxicity Management for Cancer Treatment.
Fernandez K, Hoetink A, Konrad-Martin D, Berndtson D, Clark K, Dreisbach L Ear Hear. 2024; 46(2):286-297.
PMID: 39261989 PMC: 11832334. DOI: 10.1097/AUD.0000000000001592.
Trends in ototoxicity monitoring among cisplatin-treated patients with cancer.
Lee D, Travis E, Wong S, Munyemana M, Mueller L, Rowling C J Cancer Surviv. 2024; .
PMID: 38630333 DOI: 10.1007/s11764-024-01586-3.